经心尖主动脉瓣置换在低左心室射血分数患者中是安全选择:意大利球囊扩张瓣膜注册研究结果
基于意大利球囊扩张瓣膜注册研究(ITER)的回顾性多中心分析,纳入左心室射血分数(LVEF)≤35%的208例经导管主动脉瓣植入(TAVI)患者,比较经心尖(TA-TAVI)与经股动脉(TF-TAVI)两种入路。TA组与TF组30天死亡率分别为11.6%和7.9%(P=0.45),但TF组总体Kaplan-Meier生存率显著更高(log rank P=0.003);TA入路仅在TAVI后3年成为死亡的独立预测因素。
要点
- LVEF≤35%患者中TA-TAVI与TF-TAVI的30天死亡率无显著差异。
- TF-TAVI组总体Kaplan-Meier生存率显著高于TA-TAVI组。
- TA入路仅在TAVI后3年成为死亡的独立预测因素。
核心结论
- TAVI在左心室射血分数降低的患者中可获得良好结果。
- 年龄、术前肌酐和术前永久起搏器与死亡独立相关。
- TA入路仅在随访3年后与死亡相关,可能反映这些患者总体临床状态更差。
研究设计与样本
- 回顾性多中心研究,数据来自意大利球囊扩张瓣膜注册研究(ITER)。
- 纳入LVEF≤35%的患者,按入路分为TA-TAVI组和TF-TAVI组。
- 采用多变量逻辑回归分析评估入路类型对结局的影响。
主要发现
- 2007至2012年间注册研究共纳入1882例患者,其中208例(11.1%)LVEF≤35%。
- TA-TAVI组69例(33.2%),TF-TAVI组139例(66.8%)。
- TA组和TF组30天死亡率分别为11.6%和7.9%(P=0.45)。
- TF-TAVI组总体Kaplan-Meier生存率显著更高(log rank P=0.003)。
- 年龄(OR 1.066,P=0.016)、肌酐(OR 2.301,P<0.001)、术前永久起搏器(OR 4.662,P=0.035)和TA入路(OR 2.577,P=0.006)为随访总死亡的独立预测因素。
临床怎么用
- 对于LVEF≤35%的TAVI患者,TA入路可作为安全选择,但需注意远期死亡风险。
- 年龄、术前肌酐和术前永久起搏器是死亡独立预测因素,术前应评估。
- TA入路与3年后死亡相关,选择入路时需综合考虑患者临床状态。
局限性
- 回顾性多中心注册研究,可能存在选择偏倚和混杂因素。
- 仅纳入使用Sapien生物瓣的患者,结果可能不适用于其他瓣膜。
- TA组和TF组样本量不均,TA组样本量较小。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The most commonly used accesses for transcatheter aortic valve implantation (TAVI) are the transfemoral (TF-TAVI) and the transapical (TA-TAVI) ones. There are concerns about TA-TAVI use in patients with reduced left ventricular ejection fraction (LVEF). The aim of this retrospective multicentre study was to compare the outcomes of TA-TAVI and TF-TAVI in patients with poor LVEF. METHODS: Patients with LVEF ≤35% were included in the analysis. Data were obtained from the Italian Transcatheter Balloon-Expandable Registry (ITER), which enrolled patients undergoing TAVI with the Sapien bioprosthesis in 33 national centres. Patients were divided into 2 groups according to the access: TA or TF. A multivariable logistic regression analysis was performed in order to evaluate whether the type of approach (TA and TF) has an impact on outcomes. RESULTS: Between 2007 and 2012, 1882 patients were enrolled in the Registry. LVEF ≤35% was found in 208 (11.1%) patients. TA-TAVI and TF-TAVI were performed in 69 (33.2%) and 139 (66.8%) patients, respectively. Overall 30-day mortality was 11.6% and 7.9% in TA and TF patients, respectively (P = 0.45). Overall Kaplan-Meier survival was significantly higher in the TF-TAVI group (log rank: P = 0.003). Age [odds ratio (OR) 1.066, P = 0.016], creatinine (OR: 2.301, P < 0.001), preoperative permanent pacemaker (OR: 4.662, P = 0.035) and TA approach (OR: 2.577, P = 0.006) were identified as independent predictors of overall mortality at follow-up. However, the TA approach resulted an independent variable of mortality only 3 years after TAVI. CONCLUSIONS: TAVI yields good results in patients with depressed LVEF. Age, preoperative creatinine and preoperative pacemaker are independently associated with mortality. The TA access is associated with mortality only after 3 years of follow-up, thus probably reflecting a worse general clinical status of these patients.
引用
- D'Onofrio A, Salizzoni S, Filippini C, et al. Transapical aortic valve replacement is a safe option in patients with poor left ventricular ejection fraction: results from the Italian Transcatheter Balloon-Expandable Registry (ITER). Eur J Cardiothorac Surg. 2017. PMID: 28977359. doi:10.1093/ejcts/ezx227
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。